Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics

RNA Biology

Volumn 8, Issue 1, 2011, Pages

  Kuhn, Andreas N ^a   Diken, Mustafa ^a   Kreiter, Sebastian ^a   Vallazza, Britta ^a   Türeci, Özlem ^a   Sahin, Ugur ^a  

^a Center for Translational Oncology and Immunology (TRON)   (Germany)

Author keywords

5 cap; Codon usage; Immunotherapy; Poly(A) tail; RNA stability; Translation; Untranslated regions

Indexed keywords

CIS ACTING ELEMENT; POLYADENYLIC ACID; RNA VACCINE; CANCER VACCINE; CAPPED RNA; POLYADENYLIC ACID BINDING PROTEIN; RNA; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

5' UNTRANSLATED REGION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HAPLOTYPE; HLA TYPING; IMMUNE RESPONSE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA STABILITY; RNA TRANSLATION; 3' UNTRANSLATED REGION; ARTICLE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; NEOPLASM; POLYADENYLATION;

3' UNTRANSLATED REGIONS; ANTIGEN PRESENTATION; CANCER VACCINES; DENDRITIC CELLS; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; POLY A; POLY(A)-BINDING PROTEINS; POLYADENYLATION; RNA; RNA CAPS; RNA STABILITY;

EID: 85011942138     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.8.1.13767     Document Type: Review

References (109)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten origical cases. Clin Orthop Relat Res 1893; 262:3-11.
2. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129-50. (Pubitemid 350045575)
3. Kantoff PW, Higano CS, Shore ND, Berger R, Small EJ, Penson DF, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010; 363:411-22.
4. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 2009; 8:51-66.
5. Chen X, Chang CH, Goldenberg DM. Novel strategies for improved cancer vaccines. Expert Rev Vaccines 2009; 8:567-76.
6. Eisenacher K, Steinberg C, Reindl W, Krug A. The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity. Immunobiology 2007; 212:701-14.
7. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen encoding RNA increases stability, translational efficacy and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108:4009-17. (Pubitemid 44913269)
8. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, et al. Quantitating protein synthesis, degradation and endogenous antigen processing. Immunity 2003; 18:343-54.
9. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199:251-63. (Pubitemid 38744521)
10. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anticancer vaccination. Immunol Lett 2008; 115:33-42.
11. Glisovic T, Bachorik JL, Yong J, Dreyfuss G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett 2008; 582:1977-86.
12. Wilusz CJ, Wormington M, Peltz SW. The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2001; 2:237-46. (Pubitemid 33676966)
13. Coller J, Parker R. Eukaryotic mRNA decapping. Annu Rev Biochem 2004; 73:861-90. (Pubitemid 39050388)
14. Garneau NL, Wilusz J, Wilusz CJ. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 2007; 8:113-26. (Pubitemid 46432531)
15. Houseley J, Tollervey D. The many pathways of RNA degradation. Cell 2009; 136:763-76.
16. Goldstrohm AC, Wickens M. Multifunctional deadenylase complexes diversify mRNA control. Nat Rev Mol Cell Biol 2008; 9:337-44. (Pubitemid 351430850)
17. Liu H, Kiledjian M. Decapping the message: a beginning or an end. Biochem Soc Trans 2006; 34:35-8. (Pubitemid 43235527)
18. Hsu CL, Stevens A. Yeast cells lacking 5′→3′ exoribonuclease 1 contain mRNA species that are poly(A) deficient and partially lack the 5′ cap structure. Mol Cell Biol 1993; 13:4826-35. (Pubitemid 23220388)
19. Houseley J, LaCava J, Tollervey D. RNA-quality control by the exosome. Nat Rev Mol Cell Biol 2006; 7:529-39. (Pubitemid 44036458)
20. Liu H, Rodgers ND, Jiao X, Kiledjian M. The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases. EMBO J 2002; 21:4699-708. (Pubitemid 34984357)
21. Schwartz DC, Parker R. Mutations in translation initiation factors lead to increased rates of deadenylation and decapping of mRNAs in Saccharomyces cerevisiae. Mol Cell Biol 1999; 19:5247-56. (Pubitemid 29339884)
22. Beelman CA, Parker R. Differential effects of translational inhibition in cis and in trans on the decay of the unstable yeast MFA2 mRNA. J Biol Chem 1994; 269:9687-92. (Pubitemid 24196570)
23. Furuichi Y, LaFiandra A, Shatkin AJ. 5′-Terminal structure and mRNA stability. Nature 1977; 266:235-9.
24. Sonenberg N, Morgan MA, Merrick WC, Shatkin AJ. A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5′-terminal cap in mRNA. Proc Natl Acad Sci USA 1978; 75:4843-7. (Pubitemid 9048631)
25. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68:913-63. (Pubitemid 29449212)
26. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008; 221-35.
27. Pasquinelli AE, Dahlberg JE, Lund E. Reverse 5′ caps in RNAs made in vitro by phage RNA polymerases. RNA 1995; 1:957-67.
28. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl(3′-deoxy)GpppG. RNA 2001; 7:1486-95.
29. Peng ZH, Sharma V, Singleton SF, Gershon PD. Synthesis and application of a chain-terminating dinucleotide mRNA cap analog. Org Lett 2002; 4:161-4.
30. Jemielity J, Fowler T, Zuberek J, Stepinski J, Lewdorowicz M, Niedzwiecka A, et al. Novel "antireverse" cap analogs with superior translational properties. RNA 2003; 9:1108-22.
31. Mockey M, Goncalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 2006; 340:1062-8. (Pubitemid 43083386)
32. Bontkes HJ, Kramer D, Ruizendaal JJ, Kueter EWM, van Tendeloo VFI, Meijer CJLM, et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther 2007; 14:366-75. (Pubitemid 46231930)
33. Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010; 17:961-71.
34. Hernando JJ, Park TW, Fischer HP, Zivanovic O, Braun M, Polcher M, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007; 8:451-4. (Pubitemid 46621775)
35. Kore AR, Shanmugasundaram M, Charles I, Cheng AM, Barta TJ. Synthesis and application of 2′-fluoro-substituted cap analogs. Bioorg Med Chem Lett 2007; 17:5295-9. (Pubitemid 47391294)
36. Kore AR, Shanmugasundaram M, Vlassov AV. Synthesis and application of a new 2′,3′-isopropylidene guanosine substituted cap analog. Bioorg Med Chem Lett 2008; 18:4828-32.
37. Kore AR, Shanmugasundaram M, Charles I, Vlassov AV, Barta TJ. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation and utilization. J Am Chem Soc 2009; 131:6364-5.
38. Grudzien E, Stepinski J, Jankowska-Anyszka M, Stolarski R, Darzynkiewicz E, Rhoads RE. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 2004; 10:1479-87. (Pubitemid 39122118)
39. Zuberek J, Jemielity J, Niedzwiecka A, Stepinski J, Wyslouch-Cieszynska A, Stolarski R, Darzynkiewicz E. Influence of the length of the phosphate chain in mRNA 5′ cap analogues on their interaction with eukaryotic initiation factor 4E. Nucleosides Nucleotides Nucleic Acids 2003; 22:1707-10. (Pubitemid 37139480)
40. van Dijk E, Cougot N, Meyer S, Babajko S, Wahle E, Seraphin B. Human Dcp2: a catalytically active mRNA decapping enzyme located in specific cytoplasmic structures. EMBO J 2002; 21:6915-24. (Pubitemid 36014563)
41. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007; 13:1745-55. (Pubitemid 47481682)
42. Kowalska J, Lewdorowicz M, Zuberek J, Grudzien-Nogalska E, Bojarska E, Stepinski J, et al. Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS. RNA 2008; 14:1119-31. (Pubitemid 351717492)
43. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811. (Pubitemid 30365397)
44. Tan X, Wan Y. Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens. Hum Immunol 2008; 69:32-40.
45. Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatinovich J, Calderhead D, et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol 2008; 9:90.
46. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005; 12:772-82. (Pubitemid 40668416)
47. Bernstein P, Peltz SW, Ross J. The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro. Mol Cell Biol 1989; 9:659-70. (Pubitemid 19038869)
48. Wells SE, Hillner PE, Vale RD, Sachs AB. Circularization of mRNA by eukaryotic translation initiation factors. Mol Cell 1998; 2:135-40. (Pubitemid 128378975)
49. Borman AM, Michel YM, Malnou CE, Kean KM. Free poly(A) stimulates capped mRNA translation in vitro through the eIF4G-poly(A)-binding protein interaction. J Biol Chem 2002; 277:36818-24.
50. Baer BW, Kornberg RD. Repeating structure of cytoplasmic poly(A)-ribonucleoprotein. Proc Natl Acad Sci USA 1980; 77:1890-2.
51. Sachs AB, Davis RW, Kornberg RD. A single domain of yeast poly(A)-binding protein is necessary and sufficient for RNA binding and cell viability. Mol Cell Biol 1987; 7:3268-76.
52. Deo RC, Bonanno JB, Sonenberg N, Burley SK. Recognition of polyadenylate RNA by the poly(A)-binding protein. Cell 1999; 98:835-45. (Pubitemid 29446900)
53. Couttet P, Fromont-Racine M, Steel D, Pictet R, Grange T. Messenger RNA deadenylylation precedes decapping in mammalian cells. Proc Natl Acad Sci USA 1997; 94:5628-33. (Pubitemid 27241820)
54. Steitz J, Britten CM, Wölfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 2006; 55:246-53. (Pubitemid 41682573)
55. Martin G, Keller W. Tailing and 3′-end labeling of RNA with yeast poly(A) polymerase and various nucleotides. RNA 1998; 4:226-30. (Pubitemid 28082296)
56. Korner CG, Wahle E. Poly(A) tail shortening by a mammalian poly(A)-specific 3′-exoribonuclease. J Biol Chem 1997; 272:10448-56.
57. Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, Weissman SM. Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 2006; 17:1027-35. (Pubitemid 46076744)
58. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34. (Pubitemid 30129541)
59. Waggoner SA, Liebhaber SA. Identification of mRNAs associated with alphaCP2-containing RNP complexes. Mol Cell Biol 2003; 23:7055-67. (Pubitemid 37214671)
60. Yu J, Russell JE. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol 2001; 21:5879-88. (Pubitemid 32737805)
61. Jiang Y, Xu XS, Russell JE. A nucleolin-binding 3′ untranslated region element stabilizes beta-globin mRNA in vivo. Mol Cell Biol 2006; 26:2419-29. (Pubitemid 43346940)
62. Holcik M, Liebhaber SA. Four highly stable eukaryotic mRNAs assemble 3′ untranslated region RNA-protein complexes sharing cis and trans components. Proc Natl Acad Sci USA 1997; 94:2410-4.
63. Al-Zoghaibi F, Ashour T, Al-Ahmadi W, Abulleef H, Demirkaya O, Khabar KS. Bioinformatics and experimental derivation of an efficient hybrid 3′ untranslated region and use in expression active linear DNA with minimum poly(A) region. Gene 2007; 391:130-9. (Pubitemid 46356792)
64. Zinckgraf JW, Silbart LK. Modulating gene expression using DNA vaccines with different 3′-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine 2003; 21:1640-9. (Pubitemid 36287595)
65. Pogue GP, Cao XQ, Singh NK, Nakhasi HL. 5′ sequences of rubella virus RNA stimulate translation of chimeric RNAs and specifically interact with two host-encoded proteins. J Virol 1993; 67:7106-17.
66. Sjöberg EM, Suomalainen M, Garoff H. A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology 1994; 12:1127-31.
67. Frolov I, Schlesinger S. Translation of Sindbis virus mRNA: analysis of sequences downstream of the initiating AUG codon that enhance translation. J Virol 1996; 70:1182-90. (Pubitemid 26029040)
68. Garneau NL, Sokoloski KJ, Opyrchal M, Neff CP, Wilusz CJ, Wilusz J. The 3′ untranslated region of sindbis virus represses deadenylation of viral transcripts in mosquito and Mammalian cells. J Virol 2008; 82:880-92.
69. Garfinkel MS, Katze MG. Translational control by influenza virus. Selective and cap-dependent translation of viral mRNAs in infected cells. J Biol Chem 1992; 267:9383-90.
70. Holden KL, Harris E. Enhancement of dengue virus translation: role of the 3′ untranslated region and the terminal 3′ stem-loop domain. Virology 2004; 329:119-33. (Pubitemid 39346034)
71. Chiu WW, Kinney RM, Dreher TW. Control of translation by the 5′- and 3′-terminal regions of the dengue virus genome. J Virol 2005; 79:8303-15. (Pubitemid 40853534)
72. Bergman N, Moraes KC, Anderson JR, Zaric B, Kambach C, Schneider RJ, et al. Lsm proteins bind and stabilize RNAs containing 5′ poly(A) tracts. Nat Struct Mol Biol 2007; 14:824-31. (Pubitemid 47373834)
73. Sjöberg EM, Garoff H. The translation-enhancing region of the Semliki Forest virus subgenome is only functional in the virus-infected cell. J Gen Virol 1996; 77:1323-7.
74. Strong TV, Hampton TA, Louro I, Bilbao G, Conry RM, Curiel DT. Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression. Gene Ther 1997; 4:624-7. (Pubitemid 27352961)
75. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, et al. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res 2003; 63:5587-94. (Pubitemid 37139882)
76. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86:6077-81. (Pubitemid 19210605)
77. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164:5508-14. (Pubitemid 30305236)
78. Ikemura T. Codon usage and tRNA content in unicellular and multicellular organisms. Mol Biol Evol 1985; 2:13-34. (Pubitemid 15152046)
79. Irwin B, Heck JD, Hatfield GW. Codon pair utilization biases influence translational elongation step times. J Biol Chem 1995; 270:22801-6.
80. Bossi L, Ruth JR. The influence of codon context on genetic code translation. Nature 1980; 286:123-7. (Pubitemid 10013852)
81. Gurvich OL, Baranov PV, Zhou J, Hammer AW, Gesteland RF, Atkins JF. Sequences that direct significant levels of frameshifting are frequent in coding regions of Escherichia coli. EMBO J 2003; 22:5941-50. (Pubitemid 37408829)
82. Kudla G, Murray AW, Tollervey D, Plotkin JB. Coding-sequence determinants of gene expression in Escherichia coli. Science 2009; 324:255-8.
83. Tuller T, Waldman YY, Kupiec M, Ruppin E. Translation efficiency is determined by both codon bias and folding energy. Proc Natl Acad Sci USA 2010; 107:3645-50.
84. Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, Ferrell JE, et al. Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol 2009; 7:1000238.
85. Khabar KS. The AU-rich transcriptome: more than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 2005; 25:1-10. (Pubitemid 40105586)
86. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119:135-45.
87. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998; 72:1497-503. (Pubitemid 28116938)
88. + T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother 2006; 29:512-23.
89. Van Gulck ER, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, de Roo A, et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006; 107:1818-27. (Pubitemid 43289359)
90. Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jager E, Tiercy JM, et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother 2009; 58:325-38.
91. Komar AA. A pause for thought along the co-translational folding pathway. Trends Biochem Sci 2009; 34:16-24.
92. Kramer G, Boehringer D, Ban N, Bukau B. The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat Struct Mol Biol 2009; 16:589-97.
93. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72. (Pubitemid 26324100)
94. Grunebach F, Muller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003; 10:367-74. (Pubitemid 36372444)
95. Yewdell JW, Nicchitta CV. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol 2006; 27:368-73. (Pubitemid 44038666)
96. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004; 16:27-34.
97. Kariko K, Ni HP, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279:12542-50. (Pubitemid 38445825)
98. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31.
99. Kariko K, Buckstein M, Ni HP, Weissman D. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23:165-75. (Pubitemid 41169286)
100. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314:994-7.
101. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5:730-7. (Pubitemid 39023305)
102. Schlee M, Roth A, Hornung V, Hagmann CA, Wimmenauer V, Barchet W, et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009; 31:25-34.
103. Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, Wenzel M, et al. 5′-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci USA 2009; 106:12067-72.
104. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000; 13:129-41.
105. Ben-Asouli Y, Banai Y, Pel-Or Y, Shir A, Kaempfer R. Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR. Cell 2002; 108:221-32. (Pubitemid 34161142)
106. Cohen-Chalamish S, Hasson A, Weinberg D, Namer LS, Banai Y, Osman F, et al. Dynamic refolding of IFNgamma mRNA enables it to function as PKR activator and translation template. Nat Chem Biol 2009; 5:896-903.
107. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008; 16:1833-40.
108. Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010; DOI:10.1093/nar/gkq347.
109. Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010; 70:9031-40